Cart
sales@molnova.com
Home - Products - Others - Other Targets - 5-Chlorovaleronitrile

5-Chlorovaleronitrile

CAS No. 6280-87-1

5-Chlorovaleronitrile( AI3-20151 | AI3 20151 | AI320151 )

Catalog No. M27271 CAS No. 6280-87-1

5-Chlorovaleronitrile can be used as a quantitative structure-toxicity model to predict the aquatic toxicity.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
10MG 29 In Stock
25MG 46 In Stock
50MG 63 In Stock
100MG 96 In Stock
200MG Get Quote In Stock
500MG 216 In Stock
1G 319 In Stock
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    5-Chlorovaleronitrile
  • Note
    Research use only, not for human use.
  • Brief Description
    5-Chlorovaleronitrile can be used as a quantitative structure-toxicity model to predict the aquatic toxicity.
  • Description
    5-Chlorovaleronitrile can be used as a quantitative structure-toxicity model to predict the aquatic toxicity.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    AI3-20151 | AI3 20151 | AI320151
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    6280-87-1
  • Formula Weight
    117.58
  • Molecular Formula
    C5H8ClN
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ClCCCCC#N
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Christopher LJ, et, al. Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos. 2008 Jul;36(7):1357-64.
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • Cholecystokinin Octa...

    Cholecystokinin Octapeptide (1-3) (desulfated)

  • [Pyr1]-Apelin-13

    [Pyr1]-Apelin-13 is a potent and selective endogenous Apelin receptor (APJ) agonist.[Pyr1]-apelin-13 encapsulation in lipoPEG particles (lipoPEG-PA13) results in sustained and extended drug release under physiological conditions[1].[Pyr1]-apelin-13 nanocarriers in a mouse model of pressure-overload induced heart failure demonstrate a sustainable long-term effect of [Pyr1]-apelin-13 in preventing cardiac dysfunction.

  • Sturgeon F

    Sturgeon F

Sign In Join Free